Mutations in the pol gene of human immunodeficiency virus type 1 in infected patients receiving didanosine and hydroxyurea combination therapy
Mutations in the pol gene of human immunodeficiency virus type 1 in infected patients receiving didanosine and hydroxyurea combination therapy
复制标题
DOI：
10.1086/516511
复制
发表时间：
1997-10-01
影响因子：
6.4
通讯作者：
Lori, F
中科院分区：
文献类型：
--
作者：
DeAntoni, A;Foli, A;Lori, F
分析了人类免疫缺陷病毒1型(HIV-1)耐药株逆转录酶(RT)突变的模式，两组患者接受DDI单一治疗或DDI+羟基脲(HU)联合治疗。12例接受联合治疗的患者和8例接受单一治疗的患者接受测试。联用DDI和HU并不能阻止突变的发生，在这组患者中，50%的患者出现了突变，相比之下，DDI单一治疗组的这一比例为25%。此外，在联合治疗组的1名患者中，他们对治疗的反应有限，发现了一种不寻常的突变模式：在残基69和70之间插入了2个氨基酸，这是对核苷类似物产生耐药性的关键区域。与DDI单一疗法相比，HU和DDI联合治疗的疗效更高，这不能归因于延迟或减少对DDI的耐药性。
The pattern of mutations in the reverse transcriptase (RT) of human immunodeficiency virus type 1 (HIV-1) strains that confer resistance to didanosine (ddI) was analyzed in 2 groups of patients receiving either ddI monotherapy or ddI plus hydroxyurea (HU) combination therapy. Twelve patients receiving combination therapy and 8 receiving monotherapy were tested. Combinations of ddI plus HU did not prevent the onset of mutations, which emerged in 50% of the patients in this group compared with 25% of the ddI monotherapy group. In addition, in 1 patient from the combination therapy arm, who had a limited response to the therapy, an unusual pattern of mutations was found: the insertion of 2 amino acids between residues 69 and 70, a region critical for resistance to nucleoside analogs. The higher efficacy of the combination of HU and ddI compared with that of ddI monotherapy cannot be attributed to a delayed or decreased onset of resistance to ddI.